• Immersive activities helped attendees globally learn and apply best practices for PBPK modeling

LANCASTER, Calif. / Sep 07, 2023 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, announced the successful completion of the inaugural University+ PBPK Summer Camp, an intensive eight-week course covering the theory and application of PBPK modeling using GastroPlus^®. More than 80 attendees across 26 countries satisfactorily finished all rigorous assignments and earned their certificates of completion.

The PBPK Summer Camp was offered as an enhancement to its University+ program, which provides software licenses to students and professors at accredited universities. During the program, students successfully learned how to build, evaluate, and apply PBPK models to critical drug development questions.

“This course provided clear and tangible insight to the interplay between drug and dosing environment physico-chemistry, patients’ physiology, and to their consequences on the transit of the drug inside the different body organs,” said one student in a review. “With the new skills I have developed during the course, I feel able to address several knowledge gaps in my field of research.”

Another student noted in their feedback that the workshop would “significantly help [their] career transition from DMPK scientist to [the] PBPK field.”

“[This was] a transformative and enriching summer course,” a student posted on LinkedIn. “I had the opportunity to expand my limits and connect with inspiring educators and instructors, making this a truly great learning experience.”

Denise Morris, Director of Learning Services, said: "There is no better way to bridge the gap between software access and training in academia than to collaborate with leading PBPK experts within the academic setting. With seven instructors scattered across the globe, we wanted to coordinate and design a course that was not only for academics but taught by academics as well. In keeping with the ubiquitous access to our University+ licensing program, we wanted to make sure that the course was accessible to as many students and educators as possible, resulting in a very complex structure that ensured the same quality experience, regardless of where attendees were in the world."

“In October 2021, we started our University+ program to increase access to modeling and simulation (M&S) learning and education that supports the next generation of scientists,” said Viera Lukacova, Chief Science Officer within the Simulations Plus PBPK Solutions group. “With more than 1,000 installed licenses across 300+ universities worldwide today, we have created a global platform for knowledge sharing and will continue to actively equip students with opportunities to enter the workforce ready to solve complex problems using best-in-class M&S techniques.”

Learn more about the University+ program or register for future workshops and trainings.

About Simulations Plus

Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI)/machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | Twitter | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2022 ESG update.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 

With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.